Te Arai BioFarma launches ADENURIC® (Febuxostat) in New Zealand
From 1 June 2013 Te Arai BioFarma Limited will make available to New Zealand ADENURIC® (febuxostat), the innovative drug for gout.
Gout is the most common form of arthritis in men, and is caused by high levels of uric acid in the body (hyperuricaemia). New Zealand has one of the highest rates of gout in the world particularly among Maori and Pacifica peoples.
Menarini and Te Arai Biofarma have signed an agreement for the exclusive rights to ADENURIC® in New Zealand. ADENURIC® is a molecule of Japanese origin, developed by Teijin Pharma Ltd.,Tokyo. It is the first drug to be made available as an alternative to allopurinol, and addresses a medical need which has been unmet for many years.
ADENURIC® (febuxostat) has proven therapeutic superiority to allopurinol and above all is well tolerated by gout patients suffering from a mild and moderate renal impairment.